UBS Group
PTHS

UBS Group’s Pelthos Therapeutics PTHS Stock Holding History

UBS Group’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1K Buy
764
+330
+76% +$7.83K ﹤0.01% 8087
2025
Q4 		$13.5K Buy
434
+297
+217% +$8.57K ﹤0.01% 8052
2025
Q3 		$3.84K Buy
137
+72
+111% +$1.75K ﹤0.01% 8999
2025
Q2 		$822 Sell
65
-35
-35% -$422 ﹤0.01% 9732
2025
Q1 		$1.41K Buy
+100
New +$1.71K ﹤0.01% 9510
2024
Q3 		– Sell
-19
Closed -$246 – 10160
2024
Q2 		$246 Buy
+19
New +$320 ﹤0.01% 9035

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

UBS Group's PTHS Position: Q1 2026 in Review

UBS Group increased its Pelthos Therapeutics (PTHS) stake by 76% in Q1 2026, buying an estimated $7.83K and bringing the position to 764 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #8087.

UBS Group first reported a position in PTHS in Q2 2024 and has held it in 6 quarters since. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • UBS Group held 764 shares of Pelthos Therapeutics worth $16.1K as of Q1 2026.
  • UBS Group bought 330 Pelthos Therapeutics shares in Q1 2026, an estimated $7.83K.
  • Pelthos Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8087 holding.
  • UBS Group first reported a position in Pelthos Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.